Inclusion Criteria:

At a maximum of 12 weeks after the last cycle of first line standard platinum/taxane IV or IP chemotherapy, patients must fulfill all the following inclusion criteria:

• Age >/= 18 years;
• Properly executed written informed consent;
• History of histological and CA125 (> 35 U/ml) confirmed diagnosis of stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer;
• History of debulking surgery and 6-8 cycles of standard platinum/taxane based non-investigational IV-IP chemotherapy;
• Complete clinical response defined as:
• Normal physical examination;
• No symptoms suggestive of persistent cancer;
• No definite evidence of disease by computed tomography (CT) of the abdomen and pelvis within the previous 4 weeks;
• Negative chest x-ray (or chest CT scan) within the previous 4 weeks;
• Serum CA125 within the normal laboratory range.

• Adequate hematologic, renal and hepatic function:

  • ANC >/=1.5 x 109/l;
  • Platelets >/= 75 x 109/l;
  • Haemoglobin >/= 6.2 mmol/l (>9.9 g/dl);
  • Serum creatinine </= 1.5 x ULN;
  • Bilirubin </= 1.5 x ULN; AST, ALT, AP </= 2.5 x ULN.
• ECOG Performance Status (PS) </= 2.

Exclusion Criteria:

Patients are ineligible to participate in the study, if any of the following criteria are present:

• any other invasive malignancies, with the exception of non-melanoma skin cancer or cervical carcinoma in situ, within the last 5 years or whose previous cancer treatment contraindicates this protocol therapy;
• known active autoimmune disease requiring chronic treatment with immunosuppressive agents (e.g., rheumatoid arthritis, ulcerative colitis, etc.);
• known immune deficiency (e.g. HIV, hypogammaglobulinemia, etc.);
• known infection with hepatitis B, or hepatitis C;
• history of recent myocardial infarction (</= 6 months) or decompensated heart failure (NYHA class >/= III);
• previous or concomitant use of any anti-cancer therapy other than the platinum-taxane based 1st line chemotherapy for ovarian cancer;any maintenance or consolidation therapy is not permitted after completion of standard front line chemotherapy.
• concomitant use of any other investigational agent;
• any prior investigational anti-cancer vaccine or monoclonal antibody;
• known allergy to murine proteins;
• any significant medical or psychiatric condition, drug or alcohol abuse that might prevent the patient from complying with all study procedures;
• clinically significant active infection;
• concomitant use of any immunosuppressive agent (e.g., steroids, cyclosporin, etc.);
• major surgery within the previous 2 weeks;
• radiotherapy within the previous 4 weeks;
• any significant toxicity from prior chemotherapy;
• unreliability or inability to follow protocol requirements;
• potentially childbearing and not willing to use adequate contraceptive methods throughout the entire study period;
• pregnancy.